Merck chalks up another Vioxx victory

A Florida jury ruled for Merck in yet another Vioxx case, bringing the drug maker's record to 11-5 in trials related to the drug. The newest case involved a former professional soccer player, Refik Kozic, who had a heart attack in 2001 at the age of 50. The jury decided that Vioxx didn't cause Kozic's heart attack.

Merck, of course, pulled Vioxx from the market in 2004 because of increased risk of heart attack and stroke. Some 45,000 product liability cases are pending.

- check out Merck's release

Related Articles:
NY double-teams Merck in Vioxx lawsuit. Report
Merck takes tough stance on Vioxx. Report
Vioxx defense dealt a blow by new study results. Report
Up to 100,000 Vioxx claims expected. Report
Merck faces long road in Vioxx battle. Report

Suggested Articles

Pfizer plans to sell two assets to its Mylan-Upjohn spinoff, adding $598 million in revenues—but that won't do much for its profits, analysts warned.

AstraZeneca has made a hefty investment in Brilinta with billions in R&D costs. But will that sunk cost ever turn a profit for the British drugmaker?

Novartis hopes to remove a clinical hold on the high dose of an intrathecal form of Zolgensma but expects a filing based just on the lower doses.